HUTCHMED (China) Limited (HCM)Healthcare | Drug Manufacturers - Specialty & Generic | Hong Kong, Hong Kong | NasdaqGS
13.50 USD
-0.18
(-1.316%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:10 a.m. EDT
The investment case for HUTCHMED is currently paralyzed by a massive disconnect between its explosive long-term price performance and its deteriorating short-term fundamentals. While the stock has delivered a nearly 30% gain over the last nine years, the most recent annual data shows a sharp 24% decline in revenue and a catastrophic 96.5% collapse in earnings growth. The balance sheet reflects this distress, with negative free cash flow and a trailing P/E of 141x, signaling that the market has already priced out the current reality. Despite a 'strong buy' analyst consensus driven by late-stage pipeline catalysts, the lack of recent commercial traction and the absence of any dividend support make this a speculative vehicle rather than a core holding. The options market confirms this uncertainty, with traders clustering bets on a binary outcome around the $15 level rather than a steady grind higher. Until the company can demonstrate a return to positive earnings growth and revenue expansion, the risk of a value trap outweighs the potential for a turnaround. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.178703 |
| AutoETS | 0.184635 |
| AutoARIMA | 0.185148 |
| AutoTheta | 0.192840 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 4.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.238 |
| Excess Kurtosis | -1.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.413 |
| Revenue per Share | 3.185 |
| Market Cap | 2,346,491,392 |
| Trailing P/E | 135.00 |
| Forward P/E | 52.08 |
| Beta | 0.36 |
| Profit Margins | 3.26% |
| Previous Name | Hutchison China MediTech Limited |
| Website | https://www.hutch-med.com |
As of Oct. 10, 2026, 5:10 a.m. EDT: Options activity reveals a distinct 'straddle' or 'strangle' setup centered around the $15 strike across multiple expirations, with significant open interest in both calls and puts. This indicates speculators are positioning for high volatility rather than a specific directional move, betting on a binary event like FDA approval or a clinical trial readout. The implied volatility is elevated relative to the low trading volume, suggesting the market is pricing in a potential gap-up or gap-down event.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.111111104 |
| Address1 | Cheung Kong Center |
| Address2 | 48th floor 2 Queen's Road Central |
| All Time High | 43.94 |
| All Time Low | 7.39 |
| Ask | 17.26 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 57,160 |
| Average Daily Volume3 Month | 69,058 |
| Average Volume | 69,058 |
| Average Volume10Days | 57,160 |
| Beta | 0.362 |
| Bid | 9.76 |
| Bid Size | 2 |
| Book Value | 7.255 |
| City | Hong Kong |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Hong Kong |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.5 |
| Current Ratio | 5.644 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 13.58 |
| Day Low | 13.28 |
| Debt To Equity | 7.413 |
| Display Name | HUTCHMED (China) |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,412,800 |
| Earnings Call Timestamp Start | 1,785,412,800 |
| Earnings Growth | -0.965 |
| Earnings Quarterly Growth | -0.965 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,785,414,600 |
| Earnings Timestamp Start | 1,785,414,600 |
| Ebitda | -20,515,000 |
| Ebitda Margins | -0.03736 |
| Enterprise To Ebitda | -52.583 |
| Enterprise To Revenue | 1.964 |
| Enterprise Value | 1,078,735,232 |
| Eps Current Year | 0.22185 |
| Eps Forward | 0.25921 |
| Eps Trailing Twelve Months | 0.1 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.1669 |
| Fifty Day Average Change | 0.33310032 |
| Fifty Day Average Change Percent | 0.02529831 |
| Fifty Two Week Change Percent | -11.111111 |
| Fifty Two Week High | 16.33 |
| Fifty Two Week High Change | -2.83 |
| Fifty Two Week High Change Percent | -0.17330067 |
| Fifty Two Week Low | 9.77 |
| Fifty Two Week Low Change | 3.7299995 |
| Fifty Two Week Low Change Percent | 0.3817809 |
| Fifty Two Week Range | 9.77 - 16.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,458,135,000,000 |
| Float Shares | 105,611,226 |
| Forward Eps | 0.25921 |
| Forward P E | 52.081326 |
| Free Cashflow | -18,880,250 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,790 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 13.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.13313 |
| Gross Profits | 73,104,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00014 |
| Held Percent Institutions | 0.02605 |
| Implied Shares Outstanding | 173,814,168 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. |
| Long Name | HUTCHMED (China) Limited |
| Market | us_market |
| Market Cap | 2,346,491,392 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_26652603 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | 17,883,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,516,165,586 |
| Number Of Analyst Opinions | 13 |
| Open | 13.52 |
| Operating Cashflow | 20,460,000 |
| Operating Margins | 0.00312 |
| Payout Ratio | 0.0 |
| Phone | 852 2121 8200 |
| Pre Market Change | 0.0 |
| Pre Market Change Percent | 0.0 |
| Pre Market Price | 13.5 |
| Pre Market Time | 1,791,965,300 |
| Prev Name | Hutchison China MediTech Limited |
| Previous Close | 13.68 |
| Price Eps Current Year | 60.85193 |
| Price Hint | 2 |
| Price To Book | 1.8607856 |
| Price To Sales Trailing12 Months | 4.2731695 |
| Profit Margins | 0.03257 |
| Quick Ratio | 5.453 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.41667 |
| Region | US |
| Regular Market Change | -0.18 |
| Regular Market Change Percent | -1.31579 |
| Regular Market Day High | 13.58 |
| Regular Market Day Low | 13.28 |
| Regular Market Day Range | 13.28 - 13.58 |
| Regular Market Open | 13.52 |
| Regular Market Previous Close | 13.68 |
| Regular Market Price | 13.5 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 36,957 |
| Return On Assets | -0.01238 |
| Return On Equity | 0.01464 |
| Revenue Growth | 0.002 |
| Revenue Per Share | 3.185 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 173,814,168 |
| Shares Percent Shares Out | 0.0016 |
| Shares Short | 275,665 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 201,005 |
| Short Name | HUTCHMED (China) Limited |
| Short Percent Of Float | 0.0026 |
| Short Ratio | 3.02 |
| Source Interval | 15 |
| Symbol | HCM |
| Target High Price | 33.27 |
| Target Low Price | 13.6 |
| Target Mean Price | 20.59077 |
| Target Median Price | 18.5 |
| Total Cash | 1,376,455,936 |
| Total Cash Per Share | 7.919 |
| Total Debt | 94,508,000 |
| Total Revenue | 549,121,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.1 |
| Trailing P E | 135.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.235375 |
| Two Hundred Day Average Change | 0.2646246 |
| Two Hundred Day Average Change Percent | 0.019993735 |
| Type Disp | Equity |
| Volume | 36,957 |
| Website | https://www.hutch-med.com |